|
FINAL TIMETABLE
Tuesday, May 16, 2006
|
|||||||||||||||||||||||||||||||||||||||||
|
3 Parallel Halls |
||
08:30 – 09:15 |
PLENARY Aspirin resistance |
|
|
09:15 – 10:00 |
PLENARY Disorders of platelet function / Abnormalities of the platelet P2 receptors |
||
10:00 – 10:30 |
Coffee break, Exhibition and Poster Viewing |
||
10:30 – 12:00 |
THROMBOTIC THROMBOCYTOPENIC PURPURA ADAMTS 13 and TTP: Mechanism of the disease Thrombotic thromboytopenic purpura: Another example of immunomediated thrombosis Testing the role of ADAMTS13 in platelet adhesion under flow |
NOVEL ANTITHROMBOTICS ORAL PRESENTATIONS |
CANCER AND THROMBOSIS Pathogenesis of thrombosis in cancer Cancer and venous thromboembolism: Clinical implications of a strong association Inhibition of heparanese and cancer progression by modified species of heparin
|
12:00 – 13:30 |
Lunch break, exhibition and poster viewing |
||
13:30 – 15:00 |
EPIDEMIOLOGY OF THROMBOSIS Modern life risks of venous thrombosis Acquired risk factors of venous Thromboembolism in medical patients Deep vein thrombosis and pulmonary embolism. The same disease? |
HIT ORAL PRESENTATIONS |
FIBRINOLYSIS BASIC AND CLINICAL Multiple pathways of fibrin degradation and the consequences for assay of fibrin degradation products Expression of the fibrinolytic components in endometriosis Biomarkers to guide safety and efficacy of stroke thrombolysis |
15:00 – 15:30 |
Coffee break, Exhibition and Poster Viewing |
||
15:30 – 17:00 |
CONTROVERSIES IN PROPHYLAXIS OF VTE New strategies for prevention of deep vein thrombosis in orthopedic surgery Prophylaxis in non-surgical patients – harm or good? Prophylaxis for medical patients and for orthopedic surgery - geographic differences |
CANCER AND THROMBOSIS ORAL PRESENTATIONS |
INFLAMMATION & THROMBOSIS Red blood cells in hemodynamics and hemostasis L.M. Biassuci, Italy Microinflammation monitoring: More questions than answers |
|
|